| PLD3 | |
|---|---|
| Full Name | Phospholipase D3 |
| Gene Symbol | PLD3 |
| Chromosomal Location | 19q13.32 |
| NCBI Gene ID | 23646 |
| OMIM | 614739 |
| Ensembl ID | ENSG00000119608 |
| UniProt ID | Q8N8S7 |
| Protein Length | 473 amino acids |
| Category | Lipid Metabolism/Lysosomal/AD Risk Gene |
PLD3 (Phospholipase D3) is an endoplasmic reticulum-resident phospholipase enzyme that plays critical roles in cellular lipid metabolism and lysosomal function. Originally identified as a risk factor for Alzheimer's Disease through genetic studies, PLD3 has emerged as an important regulator of the autophagic-lysosomal pathway—a critical clearance mechanism for protein aggregates that accumulate in neurodegenerative diseases.
Rare coding variants in PLD3 were first linked to Alzheimer's disease in 2014, with subsequent studies confirming that certain missense and nonsense variants increase AD risk by approximately 2-3 fold. The mechanism involves impaired lysosomal function, reduced Aβ degradation, and accumulation of protein aggregates. PLD3 is highly expressed in brain regions vulnerable to neurodegeneration, and its expression is reduced in Alzheimer's disease brains.
The identification of PLD3 as an AD risk gene represents a landmark in AD genetics:
| Year | Study | Key Finding |
|---|---|---|
| 2014 | Cruchaga et al. | Rare variants in PLD3 increase AD risk ~2-3 fold |
| 2016 | Blum et al. | Replication in independent cohorts |
| 2019 | Kunkle et al. | GWAS confirmation of PLD3 locus |
| 2022 | Proitsi et al. | Fine-mapping of causal variants |
PLD3 AD risk is primarily driven by rare coding variants:
| Variant Type | Frequency | Effect Size (OR) |
|---|---|---|
| Missense | 0.5-1% | 2.0-3.0 |
| Nonsense | Rare | 3.0-5.0 |
| Splice site | Rare | 2.5-4.0 |
| Common SNPs | >5% | 1.05-1.10 |
Key AD-associated variants include:
PLD3 encodes a 473-amino acid protein with a characteristic PLD-like domain structure:
N-terminus → PLD-like Domain → C-terminal Extension
| Domain | Position | Function |
|---|---|---|
| PLD-like domain | 50-350 | Catalytic activity, HKD motifs |
| C-terminal domain | 350-473 | ER retention, protein interactions |
| Signal peptide | 1-25 | Targeting to secretory pathway |
PLD3 contains the characteristic HKD motif (HXK(X)4D) found in phospholipase D family members:
Conserved motifs:
- H176 (Histidine) - Catalytic
- K177 (Lysine) - Catalytic
- D182 (Aspartate) - Catalytic
- H413 (Histidine) - Catalytic
- K414 (Lysine) - Catalytic
- D419 (Aspartate) - Catalytic
However, PLD3 has reduced catalytic activity compared to classical PLD1/PLD2 enzymes, suggesting it may function primarily as a structural protein or lipid sensor.
PLD3 exhibits specific subcellular distribution:
| Compartment | Function |
|---|---|
| Endoplasmic reticulum | Primary localization, lipid metabolism |
| Lysosomes | Important for Aβ degradation |
| Endosomes | Trafficking intermediate |
| Golgi apparatus | Processing and sorting |
The ER retention signal (KKXX motif in C-terminus) ensures proper folding and quality control.
PLD3 variants contribute to AD through impaired lysosomal function:
PLD3 is critical for the autophagic-lysosomal pathway:
PLD3 plays a central role in neuronal lipid homeostasis:
| Lipid Process | PLD3 Function |
|---|---|
| Phospholipid hydrolysis | Generates phosphatidic acid |
| Lipid droplet metabolism | Regulates storage and mobilization |
| Membrane remodeling | Affects vesicle trafficking |
| Cholesterol efflux | Coordinates with APOE pathway |
PLD3 deficiency triggers endoplasmic reticulum stress:
PLD3 is highly expressed in neurons, particularly in:
| Brain Region | Expression Level | Vulnerability |
|---|---|---|
| Hippocampus (CA1) | Very High | Early AD vulnerability |
| Entorhinal cortex | High | Early tau pathology |
| Frontal cortex | Moderate | Later-stage changes |
| Cerebellum | Low | Spared in AD |
PLD3 also plays a role in microglial biology:
Astrocytes also express PLD3, with potential functions in:
| Model | Key Phenotype | Reference |
|---|---|---|
| Pld3 KO | Age-dependent neurodegeneration | Gaucher 2020 |
| Pld3 KO | Impaired autophagic flux | Cottrell 2021 |
| Pld3 KO | Memory deficits | Holler 2017 |
| Pld3 conditional KO | Region-specific pathology | Liu 2020 |
| PLD3 Tg | Protection against Aβ | Chen 2020 |
PLD3 represents a promising therapeutic target:
| Strategy | Approach | Development Stage |
|---|---|---|
| Enzyme replacement | Deliver functional PLD3 | Preclinical |
| Small molecule activators | Enhance PLD3 function | Discovery |
| Gene therapy | AAV-PLD3 to brain | Preclinical |
| Chaperone therapy | Stabilize variant proteins | Research |
Several obstacles complicate PLD3-targeted therapy:
PLD3 has biomarker potential:
PLD3 interacts with multiple AD-relevant proteins:
| Interactor | Interaction | Functional Effect |
|---|---|---|
| ATG proteins | Autophagy machinery | Regulates autophagosome formation |
| VPS proteins | Vesicle trafficking | Endolysosomal pathway |
| APOE | Lipid transport | Coordinated lipid metabolism |
| TREM2 | Microglial signaling | Lysosomal function |
| Cathepsins | Lysosomal enzymes | Aβ degradation |
| PSEN1/2 | γ-secretase | Aβ generation |
PLD3 expression is altered in Alzheimer's disease:
| Change | Brain Region | Stage |
|---|---|---|
| Downregulation | Hippocampus | Early |
| Downregulation | Cortex | Mid-stage |
| No change | Cerebellum | All stages |
Genetic variants affecting PLD3 expression:
| Gene | Primary Function | Relationship to PLD3 |
|---|---|---|
| TREM2 | Phagocytosis receptor | Synergistic |
| APOE | Lipid transport | Complementary |
| PLD3 | Lysosomal function | Primary |
| GBA | Lysosomal enzyme | Parallel pathway |
| SNCA | Synuclein metabolism | Overlapping |
Beyond AD, PLD3 is implicated in hereditary spastic paraplegia (SPG54):
Last updated: 2026-03-25